Growth
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
Astellas head of oncology development on why a pan-KRAS degrader and a modality-first strategy could define the big pharma’s next chapter.
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
As immune-system science attracts record capital and scientific talent, five companies at the vanguard of the field reveal a shared conviction: the immunome is the organizing principle of human health. The harder question is how to build a business around it.
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
Headlamp Health's Lumos AI uses a ‘neurosymbolic’ multi-agent framework to improve CNS trial patient selection, targeting the heterogeneity that drives neuroscience's high attrition rate.
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
Executives from Novo Nordisk, Ipsen, Astellas, Acadia and Flagship Pioneering agree: the dealmaking environment is improving but the calculus has changed. Flexible structures, sharper therapeutic focus, and the long shadow of patent cliffs and pricing policy are reshaping how partnerships get done.
Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
It’s time for In Vivo's 18th annual Deals of the Year contest. We've chosen 15 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.
With capital being recycled, tariffs settling and interest rates softening, 2026 could provide more investment and growth opportunities in pharma and medtech, with AI giving a tailwind, say Taylor Wessing’s Ross McNaughton and Sarah Cole.
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.